Global Blood Disease Trends in 2022
Blood Disease is part of Pathology. You may also be interested in Infectious Disease, Digestive System Disorder and Obesity.
Global sales of medicines used to treat conditions related to blood and blood forming organs are set to reach $30 billion by 2026. In 2021, this market was valued at $27.3 billion, an average annual growth rate of 1.6% since 2017. Japan was the leading market for these medicines in 2021, with sales of $5.9 billion. Germany, Italy and South Korea followed in second, third and fourth place respectively. Spain saw a 21.4% year-on-year growth in the market since 2017, while Greece experienced a 13.1% decline over the same period.
Top 10 countries
In 2022 major markets in the Blood Disease Industry were:
Blood Disease Market Data and Forecasts
How much the Blood Disease industry is expected to grow to 2026?
More in Blood Disease Industry for 2028Global Blood Disease Statistics
- In Patient Average Length Of Stay 68 countries (Europe, Northern Europe, Western Europe...)
- Hospital Number 63 countries (Europe, Northern Europe, Western Europe...)
- Anemia Prevalence 223 countries (Africa, Sub-Saharan Africa, Asia...)
- Child Mortality 241 countries (Europe, Northern Europe, Eastern Europe...)
- Blood And Blood Forming Organs Medicine Sales 46 countries (Europe, Northern Europe, Western Europe...)
Global Blood Disease Industry Database
Improve your Knowledge with the latest Indicators and Trends
-
Pharmaceutical Advances: A Comprehensive Review of Sickle Cell Disease Pipeline Development
Sickle cell disease (SCD) pharmaceutical landscape has significantly evolved over the past years, primarily driven by a greater understanding of the disease pathology and emerging innovative therapeutic paradigms. The shift towards patient-specific treatments, and the introduction of gene therapy and genome editing as potential curative options are remarkable indicators of...
Discover more insights -
Molecular Blood Typing and Infectious Disease Markets: Exploring Supplier Shares and Innovative Strategies
The sector dealing with molecular blood typing and grouping employs advanced immunohaematological techniques to ensure accurate blood transfusion, which is pivotal to patient safety. The market exhibits a growth trajectory, propelled by continuous technological advancements and a rising demand due to an increase in complex surgeries, trauma cases, and prenatal...
Discover more insights -
Haemophilia: Unravelling Opportunities and Challenges in A & B Types Treatments
The treatment landscape for Haemophilia A and B, genetic disorders causing impaired blood clotting, is considerably developed yet wavering. Prophylactic factor replacement therapy, the mainstay treatment, is efficacious but fraught with several challenges such as high frequency of infusions, risk of inhibitor development and high cost. Developments in extended half-life...
Discover more insights -
Hemophilia Treatment Innovations: Exploring Pipeline Reviews and Global Clinical Trials
The advancement of clinical science has brought an era of novel therapies for hemophilia like gene therapy and bispecific antibodies which are intended to not only treat but potentially cure the condition. A number of new treatments are in the pipeline, providing real hope for enhanced patient care and quality...
Discover more insights -
Hematologic Disorders: Analyzing Market Trends in Myelofibrosis and Related Syndromes
The Myelofibrosis market is influenced by several elements. New technologies, research methodologies, and advancements in pharmaceuticals contribute to the sector's dynamism. The increasing prevalence of the disease worldwide is also a significant factor, which leads to a growing demand for effective therapies. Regulatory policies and the role of government in...
Discover more insights